Taiwan · Delayed Price · Currency is TWD Enimmune Statistics
Total Valuation
Enimmune has a market cap or net worth of TWD 1.16 billion. The enterprise value is 1.15 billion.
| Market Cap | 1.16B |
| Enterprise Value | 1.15B |
Important Dates
The last earnings date was Tuesday, August 25, 2026.
| Earnings Date | Aug 25, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Enimmune has 72.13 million shares outstanding. The number of shares has decreased by -2.64% in one year.
| Current Share Class | 72.13M |
| Shares Outstanding | 72.13M |
| Shares Change (YoY) | -2.64% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.74% |
| Owned by Institutions (%) | 3.87% |
| Float | 30.85M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 21.73 |
| PB Ratio | 11.57 |
| P/TBV Ratio | 305.46 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 21.49 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.01, with a Debt / Equity ratio of 1.59.
| Current Ratio | 1.01 |
| Quick Ratio | 0.83 |
| Debt / Equity | 1.59 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.85 |
| Interest Coverage | -27.71 |
Financial Efficiency
Return on equity (ROE) is -74.45% and return on invested capital (ROIC) is -23.84%.
| Return on Equity (ROE) | -74.45% |
| Return on Assets (ROA) | -16.87% |
| Return on Invested Capital (ROIC) | -23.84% |
| Return on Capital Employed (ROCE) | -91.11% |
| Weighted Average Cost of Capital (WACC) | 5.22% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.12 |
| Inventory Turnover | 1.60 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -4.48% in the last 52 weeks. The beta is 0.25, so Enimmune's price volatility has been lower than the market average.
| Beta (5Y) | 0.25 |
| 52-Week Price Change | -4.48% |
| 50-Day Moving Average | 16.34 |
| 200-Day Moving Average | 18.56 |
| Relative Strength Index (RSI) | 53.61 |
| Average Volume (20 Days) | 57,844 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Enimmune had revenue of TWD 53.45 million and -120.88 million in losses. Loss per share was -1.68.
| Revenue | 53.45M |
| Gross Profit | 4.31M |
| Operating Income | -124.27M |
| Pretax Income | -120.88M |
| Net Income | -120.88M |
| EBITDA | -117.77M |
| EBIT | -124.27M |
| Loss Per Share | -1.68 |
Balance Sheet
The company has 172.45 million in cash and 159.57 million in debt, with a net cash position of 12.88 million or 0.18 per share.
| Cash & Cash Equivalents | 172.45M |
| Total Debt | 159.57M |
| Net Cash | 12.88M |
| Net Cash Per Share | 0.18 |
| Equity (Book Value) | 100.39M |
| Book Value Per Share | 1.39 |
| Working Capital | 3.74M |
Cash Flow
In the last 12 months, operating cash flow was -83.45 million and capital expenditures -2.75 million, giving a free cash flow of -86.19 million.
| Operating Cash Flow | -83.45M |
| Capital Expenditures | -2.75M |
| Depreciation & Amortization | 6.50M |
| Net Borrowing | -8.19M |
| Free Cash Flow | -86.19M |
| FCF Per Share | -1.19 |
Margins
Gross margin is 8.06%, with operating and profit margins of -232.49% and -226.16%.
| Gross Margin | 8.06% |
| Operating Margin | -232.49% |
| Pretax Margin | -226.16% |
| Profit Margin | -226.16% |
| EBITDA Margin | -220.33% |
| EBIT Margin | -232.49% |
| FCF Margin | n/a |
Dividends & Yields
Enimmune does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 2.64% |
| Shareholder Yield | 2.64% |
| Earnings Yield | -10.41% |
| FCF Yield | -7.42% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Enimmune has an Altman Z-Score of -0.38 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.38 |
| Piotroski F-Score | 2 |